Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Relapsed or refractory chronic lymphocytic leukaemia, drawn from the whole corpus: 30 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Double-refractory disease after BTK inhibitor and venetoclax has no durable option.
Nothing recorded yet.
Background: Drug resistance (primary and acquired). Also on OnCo: Resistance atlas · Lines of therapy.
Whether venetoclax retreatment works as well the second time, and after how long an interval.
Distinguishing CLL progression from Richter transformation early enough.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 17 changes by month →When this page itself was last checked or edited.
Relapsed/refractory CLL/SLL after a covalent BTK inhibitor (traditional approval, BRUIN CLL-321)
Relapsed/refractory CLL/SLL after BTK inhibitor and BCL-2 inhibitor (accelerated)
PFS 11.
A milestone in how this cancer is treated.
CR/CRi 18-20%; ORR 47%; uMRD blood 64%.